NCT01215279

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.

Conditions

• Chronic Obstructive Pulmonary Disease
• Lung Disease

Interventions

Type	Name	Description
DRUG	AZD2423	100 mg oral treatment once daily for 28 days
DRUG	Placebo to AZD2423	Oral treatment once daily for 28 days

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-10-06
• Last updated: 2014-10-23
• Results posted: 2014-10-23

Locations

6 sites across 2 countries: Bulgaria, Slovakia